Overall world revenue for the ophthalmic drugs Market: In terms of value the market will surpass US$35.0 billion in 2025, the work calculates. The publisher predicts strong revenue growth through to 2035. The work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
The The Ophthalmic Drugs Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The global ophthalmic drugs market is experiencing robust growth, driven by several key factors. Rising incidences of eye-related conditions - such as glaucoma, macular degeneration, diabetic retinopathy, and dry eye syndrome - are fuelling the demand for advanced pharmaceutical solutions. This trend is further supported by an aging global population and lifestyle changes that increase susceptibility to these conditions, underscoring the need for innovative drug options. A strong pipeline of new ophthalmic drugs is also bolstering market expansion, as pharmaceutical companies invest substantially in R&D to introduce enhanced and novel treatments. These active developments are set to deliver more targeted and precise therapies, improving treatment options and accelerating market momentum. With sustained innovation and continuous advancements, the global ophthalmic drugs market is expected to maintain its growth trajectory in the coming years.
Addressing drug-related side effects in the ophthalmic drugs market, particularly in developing countries, necessitates a comprehensive strategy. This includes increasing healthcare accessibility, developing medical infrastructure, educating patients, reducing counterfeit drug circulation, and enacting stringent regulatory frameworks to ensure the safety and efficacy of ophthalmic treatments. Apellis Pharmaceuticals' drug pegcetacoplan, which was approved by the FDA for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), has raised safety concerns due to instances of intraocular inflammation (IOI), according to the American Society of Retina Specialists (ASRS). As of April 2023, the ASRS Research and Safety in Therapeutics (ReST) Committee began tracking reports of IOI, some of which resulted in severe retinal vasculitis, occlusive retinal vasculopathy, or vision loss. On 16th January 2024, a retrospective analysis revealed 14 cases of retinal vasculitis among 13 patients following their first pegcetacoplan injection, with inflammation typically manifesting around 10.5 days after the injection. Notably, retinal veins were more affected than arteries, and 57% of impacted eyes had significant vision acuity (VA) loss, with two cases necessitating enucleation due to severe complications. In addition, 43% of cases showed anterior segment neovascularisation. These findings highlight critical safety issues, emphasising the importance of continuous monitoring and real-world safety analysis of pegcetacoplan in order to better assess and manage associated risks.
The The Ophthalmic Drugs Market Report 2025-2035: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
The global ophthalmic drugs market is experiencing robust growth, driven by several key factors. Rising incidences of eye-related conditions - such as glaucoma, macular degeneration, diabetic retinopathy, and dry eye syndrome - are fuelling the demand for advanced pharmaceutical solutions. This trend is further supported by an aging global population and lifestyle changes that increase susceptibility to these conditions, underscoring the need for innovative drug options. A strong pipeline of new ophthalmic drugs is also bolstering market expansion, as pharmaceutical companies invest substantially in R&D to introduce enhanced and novel treatments. These active developments are set to deliver more targeted and precise therapies, improving treatment options and accelerating market momentum. With sustained innovation and continuous advancements, the global ophthalmic drugs market is expected to maintain its growth trajectory in the coming years.
Side Effects of Drugs Likely to Challenge Industry Growth
Topical ophthalmic drugs can cause a variety of side effects, including temporary vision cloudiness, allergic reactions, visual disturbances, and stinging, burning, or itching. Less common but more severe side effects include sudden vision changes, intense headaches, tunnel vision, eye discomfort, pain behind the eyes, and signs of an eye infection, such as swelling and discharge. As a result, adverse effects, particularly those associated with topical steroidal drugs, may limit market growth.Addressing drug-related side effects in the ophthalmic drugs market, particularly in developing countries, necessitates a comprehensive strategy. This includes increasing healthcare accessibility, developing medical infrastructure, educating patients, reducing counterfeit drug circulation, and enacting stringent regulatory frameworks to ensure the safety and efficacy of ophthalmic treatments. Apellis Pharmaceuticals' drug pegcetacoplan, which was approved by the FDA for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), has raised safety concerns due to instances of intraocular inflammation (IOI), according to the American Society of Retina Specialists (ASRS). As of April 2023, the ASRS Research and Safety in Therapeutics (ReST) Committee began tracking reports of IOI, some of which resulted in severe retinal vasculitis, occlusive retinal vasculopathy, or vision loss. On 16th January 2024, a retrospective analysis revealed 14 cases of retinal vasculitis among 13 patients following their first pegcetacoplan injection, with inflammation typically manifesting around 10.5 days after the injection. Notably, retinal veins were more affected than arteries, and 57% of impacted eyes had significant vision acuity (VA) loss, with two cases necessitating enucleation due to severe complications. In addition, 43% of cases showed anterior segment neovascularisation. These findings highlight critical safety issues, emphasising the importance of continuous monitoring and real-world safety analysis of pegcetacoplan in order to better assess and manage associated risks.
Key Questions Answered
- How is the ophthalmic drugs market evolving?
- What is driving and restraining the ophthalmic drugs market?
- How will each ophthalmic drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2035?
- How will the market shares for each ophthalmic drugs submarket develop from 2025 to 2035?
- What will be the main driver for the overall market from 2025 to 2035?
- Will leading ophthalmic drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
- How will the market shares of the national markets change by 2035 and which geographical region will lead the market in 2035?
- Who are the leading players and what are their prospects over the forecast period?
- How will the industry evolve during the period between 2025 and 2035? What are the implications of ophthalmic drugs projects taking place now and over the next 10 years?
- Is there a greater need for product commercialisation to further scale the ophthalmic drugs market?
- Where is the ophthalmic drugs market heading and how can you ensure you are at the forefront of the market?
- What are the best investment options for new product and service lines?
- What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the Ophthalmic Drugs Market today, and over the next 10 years:
- This 344-page report provides 129 tables, 178 charts/graphs exclusively to you.
- The report highlights key lucrative areas in the industry so you can target them - NOW.
- It contains in-depth analysis of global, regional and national sales and growth.
- It highlights for you the key successful trends, changes and revenue projections made by your competitors.
Forecasts to 2035 and other analyses reveal commercial prospects
- In addition to revenue forecasting to 2035, the new study provides you with recent results, growth rates, and market shares.
- You will find original analyses, with business outlooks and developments.
- Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising ophthalmic drugs prices and recent developments.
Segments Covered in the Report
Type
- Prescription Drugs
- OTC Drugs
Indication
- Retinal Disorders
- Infection/Inflammation/Allergy
- Glaucoma
- Dry Eye
- Others
Route of Administration
- Topical
- Parenteral
Distribution Channel
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
North America
- U.S.
- Canada
Europe
- Germany
- Spain
- UK
- France
- Italy
- Netherlands
- Switzerland
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Malaysia
- Singapore
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Mexico
- Chile
- Rest of Latin America
MEA
- GCC
- South Africa
- Rest of MEA
Leading companies and the potential for market growth
- AbbVie Inc.
- Alcon
- Alimera Sciences
- Apellis Pharmaceuticals
- Bausch + Lomb Corporation
- Bayer AG
- Breye Therapeutics ApS
- EyeBio
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Nicox
- Novaliq GmbH
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Santen Pharmaceutical Co., Ltd.
- SpliceBio
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
How will the Ophthalmic Drugs Market report help you?
In summary, the 340+ page report provides you with the following knowledge:- Revenue forecasts to 2035 for Ophthalmic Drugs Market Market, with forecasts for type, distribution channel, indication, route of administration, each forecast at a global and regional level - discover the industry's prospects, finding the most lucrative places for investments and revenues.
- Revenue forecasts to 2035 for five regional and 26 key national markets - See forecasts for the Ophthalmic Drugs Market market in North America, Europe, Asia-Pacific, Latin America and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
- Prospects for established firms and those seeking to enter the market - including company profiles for 21 of the major companies involved in the Ophthalmic Drugs Market.
Information found nowhere else
With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. This study is for everybody needing commercial analyses for the Ophthalmic Drugs Market, market-leading companies. You will find data, trends and predictions.Table of Contents
1 Report Overview
3 Market Overview
4 Ophthalmic Drugs Market Analysis by Type
5 Ophthalmic Drugs Market Analysis by Distribution Channel
6 Ophthalmic Drugs Market Analysis by Indication
7 Ophthalmic Drugs Market Analysis by Route of Administration
8 Ophthalmic Drugs Market Analysis by Region
9 North America Ophthalmic Drugs Market Analysis
10 Europe Ophthalmic Drugs Market Analysis
11 Asia Pacific Ophthalmic Drugs Market Analysis
12 Latin America Ophthalmic Drugs Market Analysis
13 MEA Ophthalmic Drugs Market Analysis
14 Company Profiles
15 Conclusion and Recommendations
List of Tables
List of Figures
Companies Mentioned
- AbbVie Inc.
- Alcon
- Alimera Sciences
- Apellis Pharmaceuticals
- Bausch + Lomb Corporation
- Bayer AG
- Breye Therapeutics ApS
- EyeBio
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson Services, Inc.
- Nicox
- Novaliq GmbH
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals Inc.
- Santen Pharmaceutical Co., Ltd.
- SpliceBio
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- 4D Molecular Therapeutics
- AimMax Therapeutics
- Alteogen
- Amman Pharmaceuticals Industries
- Atsena Therapeutics
- Aurion Biotech
- Bioeq AG
- Caplin Steriles Limited
- Capsida Biotherapeutics Inc.
- Coherus BioSciences
- Eyenovia, Inc.
- Formosa Pharmaceuticals
- Formycon AG
- Glaukos Corporation
- Glenmark Pharmaceuticals Ltd.
- Golgi Neurosciences S.r.l.
- Harrow
- Huons Co. Ltd.
- Kowa Company, Ltd.
- Kwangdong Pharmaceutical Co., Ltd.
- Luye Pharma Group
- MS Pharma
- Neurotech Pharmaceuticals, Inc.
- Orasis Pharmaceuticals
- Ocugen, Inc.
- Ocular Therapeutix, Inc.
- Oculis Holding AG
- Ocumension Therapeutics
- Opus Genetics
- Ora, Inc.
- Palatin Technologies, Inc.
- Polpharma Biologics Group BV
- REGENXBIO Inc.
- RTW Investments, LP
- Skyline Therapeutics
- Trukera Medical
- Viridian Therapeutics, Inc.
- Zhaoke Ophthalmology Limited
- Centers for Disease Control and Prevention (CDC)
- Drugs Controller General of India (DCGI)
- European Medicines Agency (EMA)
- Glaucoma Research Foundation (GRF)
- Global Alliances and External Research (GAER)
- Institute of Molecular and Clinical Ophthalmology Basel (IOB)
- International Diabetes Federation (IDF)
- Ministry of Health, Labour and Welfare (MHLW)
- National Health Service (NHS)
- National Medical Products Administration (NMPA)
- Singapore Eye Research Institute (SERI)
- U.S. Food and Drug Administration (FDA)
- UCL Institute of Ophthalmology (IoO)
- UK Medicines & Healthcare Regulatory Agency (MHRA)
- World Health Organization (WHO)
